Top

Clinical and Translational Oncology

Published in:

01-11-2015 | Research Article

Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases

Authors: W.-G. Qiang, L.-R. Shi, X.-D. Li, Q.-Q. Wu, J.-M. Zhao, L.-J. Chen, Y. Yang, J. Wu, M. Ji, C.-P. Wu

Published in: Clinical and Translational Oncology | Issue 11/2015

Abstract

Backgrounds

The present study aimed to evaluate benefit of hepatic arterial infusion chemotherapy (HAI) combined with systemic chemotherapy (SCT) for patients with colorectal liver metastases (CLMs) in a palliative setting.

Methods

This was a retrospective single-center study including 43 consecutive patients with CLM after failure of standard SCT. Among them, 20 (47 %) patients underwent HAI combined with SCT (Group A) and 23 historical control patients who had received SCT with or without targeted agent treatment (Group B).

Results

The two groups had similar characteristics. Compared with SCT alone, HAI combined with SCT prolonged survival (median 19.8 vs. 9.0 months; P = 0.045). Median hepatic progression-free survival was significantly longer for HAI combined with SCT vs. SCT alone (median 8.1 vs. 4.7 months; P = 0.027), as were response rates (25 and 0 %; P = 0.038) and progression-free survival (median 5.7 vs. 3.0 months; P = 0.02). Three patients (15 %) achieved conversion to potentially curative surgery. Grade 3/4 toxicities for Group A and Group B were neutropenia (5 and 8.7 %, respectively), anemia (5 and 0 %, respectively), and hyperbilirubinemia (0 and 4.3 %, respectively). Other complications were mostly grade 1 or 2.

Conclusions

HAI combined with SCT treatment can improve overall survival compared with SCT alone in highly advanced CLM refractory to intravenous chemotherapy.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Sperling J, Schafer T, Ziemann C, Benz-Weiber A, Kollmar O, Schilling MK, et al. Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis. 2012;29(2):91–9. doi:10.1007/s10585-011-9432-6.CrossRefPubMed

Teker F, Demirag G, Erdem D, Kemal Y, Yucel I. Quality of life in colorectal cancer patients during chemotherapy in the era of monoclonal antibody therapies. J BUON. 2015;20(2):443–51.PubMed

Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15(1):428. doi:10.1186/s12885-015-1430-7.PubMedCentralCrossRefPubMed

Landry JC, Feng Y, Prabhu RS, Cohen SJ, Staley CA, Whittington R, et al. Phase II trial of preoperative radiation with concurrent Capecitabine, Oxaliplatin, and Bevacizumab followed by surgery and postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN cancer research group E3204. Oncologist. 2015. doi:10.1634/theoncologist.2015-0106.PubMedCentralPubMed

Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, et al. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS One. 2015;10(3):e0120064. doi:10.1371/journal.pone.0120064.PubMedCentralCrossRefPubMed

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64. doi:10.1200/JCO.2006.08.1620.CrossRefPubMed

Liu W, Song QK, Xing BC. A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases. Int J Colorectal Dis. 2015. doi:10.1007/s00384-015-2246-2.

Tanaka T, Arai Y, Inaba Y, Matsueda K, Aramaki T, Takeuchi Y, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003;14(1):63–8.CrossRefPubMed

10.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed

11.

Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701. doi:10.1093/annonc/mdu560.CrossRefPubMed

12.

Komori H, Beppu T, Sakamoto Y, Miyamoto Y, Hayashi H, Imai K, et al. Irinotecan plus S-1 followed by hepatectomy for a patient with initially unresectable colorectal liver metastases, who showed severe drug rash with oxaliplatin plus 5-FU and Leucovorin (FOLFOX). Case Rep Gastrointest Med. 2014:2014;906759. doi:10.1155/2014/906759.PubMedCentralPubMed

13.

Zalba S, Contreras AM, Haeri A, Ten Hagen TL, Navarro I, Koning G, et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Rel. 2015;210:26–38. doi:10.1016/j.jconrel.2015.05.271.CrossRef

14.

Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology. 2015;4(3):e976052. doi:10.4161/2162402X.2014.976052.CrossRefPubMed

15.

Lainas P, Camerlo A, Conrad C, Shivathirthan N, Fuks D, Gayet B. Laparoscopic right hepatectomy combined with partial diaphragmatic resection for colorectal liver metastases: is it feasible and reasonable? Surgery. 2015. doi:10.1016/j.surg.2015.02.003.PubMed

16.

Vigano L, Capussotti L, Lapointe R, Barroso E, Hubert C, Giuliante F, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6025 patients. Ann Surg Oncol. 2014;21(4):1276–86. doi:10.1245/s10434-013-3421-8.CrossRefPubMed

17.

Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today. 2013;43(10):1088–94. doi:10.1007/s00595-012-0416-1.CrossRefPubMed

18.

Bolton JS, O’Connell MJ, Mahoney MR, Farr GH Jr, Fitch TR, Maples WJ, et al. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer. 2012;11(1):31–7. doi:10.1016/j.clcc.2011.03.029.PubMedCentralCrossRefPubMed

19.

Sadahiro S, Suzuki T, Tokunaga N, Tajima T, Makuuchi H, Ohtaki M. Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid. AJR Am J Roentgenol. 2000;175(6):1641–2. doi:10.2214/ajr.175.6.1751641.CrossRefPubMed

20.

Arai Y, Ohtsu A, Sato Y, Aramaki T, Kato K, Hamada M, et al. Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol. 2012;23(10):1261–7. doi:10.1016/j.jvir.2012.06.031.CrossRefPubMed

21.

Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96. doi:10.1200/JCO.2005.07.100.CrossRefPubMed

22.

Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26. doi:10.1245/s10434-007-9581-7.CrossRefPubMed

23.

Nishiofuku H, Tanaka T, Aramaki T, Boku N, Inaba Y, Sato Y, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer. 2010;9(5):305–10. doi:10.3816/CCC.2010.n.044.CrossRefPubMed

24.

Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13(1):27–36. doi:10.1016/j.clcc.2013.11.010.CrossRefPubMed

25.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20(13):4289–97. doi:10.1245/s10434-013-3217-x.CrossRefPubMed

Title: Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases
Authors: W.-G. Qiang
L.-R. Shi
X.-D. Li
Q.-Q. Wu
J.-M. Zhao
L.-J. Chen
Y. Yang
J. Wu
M. Ji
C.-P. Wu
Publication date: 01-11-2015
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 11/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1317-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Backgrounds

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2015

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction

Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment

Intraoperative electron-beam radiation therapy with or without external-beam radiotherapy in the management of paraaortic lymph-node oligometastases from gynecological malignancies

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer